Fred Alger Management’s Compass Therapeutics CMPX Stock Holding History

Fred Alger Management’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-403,062	Closed	-$1.32M	–	524
2023 Q1	$1.32M	Sell	403,062 -205,474	-34%	-$807K	0.01%	371
2022 Q4	$3.06M	Hold	608,536	–	–	0.02%	302
2022 Q3	$1.39M	Hold	608,536	–	–	0.01%	360
2022 Q2	$1.61M	Hold	608,536	–	–	0.01%	349
2022 Q1	$834K	Sell	608,536 -210,209	-26%	-$434K	﹤0.01%	402
2021 Q4	$2.6M	Buy	+818,745	New	+$2.71M	0.01%	343

Other funds holding CMPX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Fred Alger Management's CMPX Position: Q2 2023 in Review

Fred Alger Management sold out of Compass Therapeutics (CMPX) in Q2 2023, closing a stake of 403,062 shares — an estimated $1.32M sold.

Fred Alger Management first reported a position in CMPX in Q4 2021 and held it in 6 quarters. The position peaked at $3.06M in Q4 2022. 73 funds tracked by Wall St. Rank hold CMPX as of Q2 2023.

Fred Alger Management reported no remaining Compass Therapeutics position as of Q2 2023 after selling out during the quarter.
Fred Alger Management sold 403,062 Compass Therapeutics shares in Q2 2023, an estimated $1.32M.
Fred Alger Management first reported a position in Compass Therapeutics in Q4 2021 and held it in 6 quarters.
Fred Alger Management's Compass Therapeutics position peaked at $3.06M in Q4 2022.
73 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2023.

Based on Fred Alger Management's 13F filing for Q2 2023, filed 14 Aug 2023.